Skip to main content
SpringerLink
Log in

Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation

  • Letter to the Editor
  • Published:
Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.

    Article  PubMed  CAS  Google Scholar 

  2. Jurisic V, Colovic N, Terzic T, Djordjevic V, Colovic M. Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature. Pathol Res Pract. 2012;208(7):420–3.

    Article  PubMed  Google Scholar 

  3. Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22:756–61.

    Article  PubMed  CAS  Google Scholar 

  4. Rohr SS, Pelloso LA, Dos Santos Borgo A, de Rezende JG Jr, Silva MR, Yamamoto M, de Lourdes L F Chauffaille M. RARS with fibrosis and del(20q) transformed into ALL. Med Oncol. 2012;29(5):3570–3

    Google Scholar 

  5. Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cell Mol Dis. 2012;49(3–4):170–6.

    Google Scholar 

Download references

Acknowledgments

This work was supported by a research project grant by the Serbian Ministry of Science and education, number 175056.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Vladimir Jurisic

  2. Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia

    Sonja Pavlovic

  3. Institute of Hematology, School of Medicine, University of Belgrade, Belgrade, Serbia

    Natasa Colovic & Milica Colovic

Authors
  1. Vladimir Jurisic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonja Pavlovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natasa Colovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Milica Colovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladimir Jurisic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jurisic, V., Pavlovic, S., Colovic, N. et al. Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation. Med Oncol 30, 398 (2013). https://doi.org/10.1007/s12032-012-0398-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-012-0398-2

Keywords

Search

Navigation